The Latest Vaccine News

mercredi 28 février 2024

168 lectures

International Vaccine Access Center (IVAC)

VACCINE ACCESS DIGEST | FEBRUARY 2024

NEWS & ANNOUNCEMENTS

[Podcast] Extended Interview: Behind the Scenes with a Documentary Crew Following the Malaria Vaccine from Trial to Approval

In an interview with the Johns Hopkins Malaria Minute, Dr. William Moss, IVAC's Executive Director and Deputy Director at the Johns Hopkins Malaria Research Institute, discusses the significance of newly developed malaria vaccines. Dr. Moss explained, "This is a very exciting time for malaria vaccines as we now have two vaccines that have been recommended by the World Health Organization."

Listen to the Podcast

2024 Knight Media Forum Highlights Need to Fight Disinformation

This month, IVAC faculty presented findings from their research on leveraging social media influencers to combat vaccine disinformation at the 2024 Knight Media Forum, a leading conference for media and journalism. Dr. Rupali Limaye received a grant from the Knight Foundation as part of a call for projects combating the impacts of disinformation on communities of color in the United States. The team designed and tested an educational training resource with Latinx social media users and community leaders to provide evidence-based strategies to combat disinformation in Spanish-speaking communities. The resource can be accessed in English or Spanish here.

Practical Playbook for Addressing Health Misinformation

This playbook from the Johns Hopkins Center for Health Security is designed to help public health and medical professionals and other health communicators understand when to step in and what actions to take to address rumors and misinformation related to public health issues.

Download Here

User Survey: Feedback Requested
Help us improve our newsletter! Please complete a 5-minute, anonymous survey to give us a better idea of the type of news and resources you find most useful.

Take the Survey

Photo credit: Karen Kasmauski

Study Finds Single-Dose Cholera Vaccine as Effective as Standard Two-Dose Regimen in Cholera Endemic Setting

In the midst of a global cholera vaccine shortage and mounting cholera cases, a new study led by researchers at Johns Hopkins Bloomberg School of Public Health finds that a single dose of the vaccine provides significant protection against cholera for at least three years. This evidence is especially encouraging for expanding coverage among at-risk populations. “In cholera endemic areas, use of a one dose oral cholera vaccine regimen, rather than the standard two doses may allow us to greatly improve the population-level benefits of the vaccine with little to no reduction in protection to the individual, at least over the first few years,” explained Dr. Andrew Azman, Associate Scientist in the Bloomberg School's Department of Epidemiology and a senior author of the paper.

Subscribe to IVAC Channel on YouTube
IVAC's YouTube channel has over 100 videos including short documentaries, recorded webinars, and tutorials for vaccine-related resources. Catch up on published videos and subscribe today to get notified when new videos are available.

IVAC's YouTube

RESEARCH & PUBLICATIONS

The US COVID-19 and Influenza Scenario Modeling Hubs: Delivering Long-Term Projections to Guide Policy [Epidemics]
Authors include Sara Loo, Erica Carcelen, and Shaun Truelove

During the COVID-19 pandemic, the COVID-19 Scenario Modeling Hub generated projections of disease burden in the United States to help with pandemic planning and decision-making. This publication describes the history of this massive collective research effort, the process of convening and maintaining an open modeling hub active over multiple years, and the expansion of the hub to generate influenza projections.

Global Perspectives of Determinants Influencing HPV Vaccine Introduction and Scale-Up in Low- and Middle-Income Countries [PLOS ONE]
By Dominique Guillaume, Dur-e-Nayab Waheed, Meike Schleiff, Kirthini Kasi Muralidharan, Alex Vorsters, and Rupali J. Limaye

This qualitative study interviewed 13 global stakeholders to understand factors affecting the introduction and scale-up of HPV vaccination programs in LMICs. The results of this investigation identified upstream and downstream determinants that impact program introduction and scale-up and confirmed that strong political commitment and governance are needed to garner support for HPV vaccines.

Group-Based Trajectory Models of Integrated Vaccine Delivery and Equity in Low- and Middle-Income Countries [International Journal for Equity in Health]
By Sanjana J. Ravi, Andrés I. Vecino-Ortiz, Christina M. Potter, Maria W. Merritt, and Bryan N. Patenaude

To understand the relationship between integrated vaccine delivery and vaccination equity in LMICs, the authors analyzed longitudinal data relating to routine immunization coverage and vaccination equity in 78 LMICs that have received support from Gavi, the Vaccine Alliance. They concluded that integrated vaccine delivery is most strongly associated with improvements in vaccination equity in settings with high baseline levels of inequity.